HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
INSIDE INDUSTRY
Molecular test to predict immunotherapy response for kidney cancer
Study was conducted using the CLEARScore test that identifies eight genes linked to immunotherapy

Immunotherapy drugs such as PD-L1 checkpoint inhibitors represent the front-line treatment for kidney cancer. But it is expensive, benefits only a subset of patients and is futile in the majority of patients.

Researchers from the National Cancer Centre Singapore and Lucence Diagnostics have conducted a study using Lucence鈥檚 molecular test, CLEARScore, to predict whether a kidney cancer patient will or will not benefit from immunotherapy thus helping to reduce futile costs and side effects.

CLEARScore is an algorithm involving eight genes in the tumour, which classifies kidney cancer by molecular type.

Kidney cancer is among the ten most common cancers in men and women across the world. In 2018, there were over 400,000 new cases of kidney cancer globally.

Previously, the test has been used to successfully predict treatment response of kidney cancer patients to tyrosine kinase inhibitors, a type of targeted therapy. The results were published in 2015 in European Urology.

Click here for the complete issue.

NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy